We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia.
- Authors
Zhang, Ya‐Ping; Yang, Xi; Lin, Zeng‐Hua; Wang, Xin‐Feng; Cao, Xin; You, Xue‐Fen; Huang, Hong‐Ming; Shi, Wen‐Yu; Liu, Hong
- Abstract
Objective This retrospective study was designed to determine the efficacy and safety of low-dose bortezomib and dexamethasone ( lBD) in elderly Chinese patients with Waldenstrӧm macroglobulinemia ( WM). Methods Ten patients with WM aged over 60 years received first-line treatment with lBD. Results The median age was 70 years (range, 61-77 years). The overall response rate was 80%, including 1 patient who achieved a complete response, 1 patient with very good partial response, and 6 patients with a partial response. Median time to response was 1.8 months after treatment with lBD. Six (60%) patients achieved a partial response, including 2 (20%) patients who had a more than 75% reduction in serum immunoglobulin M levels. A rapid reduction in paraprotein was observed in three patients who received plasmapheresis. After a median follow-up period of 36 months, all patients were still alive and six had no disease progression. The estimated median time to progression was 39 months (range, 15-60 months). The most common adverse events were anemia, thrombocytopenia, neuropathy, and neutropenia. Peripheral neuropathy was the most common non-hematological toxicity in six (60%) patients, but did not result in the discontinuation of bortezomib. Conclusions Our findings show that lBD is an effective and tolerable treatment regimen for elderly patients with WM.
- Subjects
WALDENSTROM'S macroglobulinemia; DRUG efficacy; ANTINEOPLASTIC agents; BORTEZOMIB; DEXAMETHASONE
- Publication
European Journal of Haematology, 2017, Vol 99, Issue 6, p489
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12935